(NP (NP (NP (NN Association)) (PP (IN of) (NP-COOD (NP (NN TRAF1)) (, ,) (NP (NN TRAF2)) (, ,) (CC and) (NP (NN TRAF3)))) (PP (IN with) (NP (NP (DT an) (JJ Epstein-Barr) (NN virus) (NN LMP1) (NN domain)) (ADJP (JJ important) (PP (IN for) (NP (NN B-lymphocyte) (NN transformation)))))) (: :)) (NP (NP (NN role)) (PP (IN in) (NP (NN NF-kappaB) (NN activation)))) (. .))
(S (NP-SBJ-55 (NP (NP (DT The) (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (VBG transforming) (NN protein) (NN LMP1)) (VP (VBZ appears) (S (NP-SBJ (-NONE- *-55)) (VP (TO to) (VP (VB be) (NP-PRD (DT a) (ADJP (RB constitutively) (VBN activated)) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TNFR)) (-RRB- -RRB-)))) (PP (IN on) (DT the) (NN basis) (IN of) (NP-COOD (NP (DT an) (JJ intrinsic) (NN ability) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB aggregate) (PP (IN in) (NP (DT the) (NN plasma) (NN membrane))))))) (CC and) (NP (NP (DT an) (NN association)) (PP (IN of) (NP (PRP$ its) (JJ cytoplasmic) (NP (NP (NN carboxyl) (NN terminus)) (PRN (-LRB- -LRB-) (NP (NN CT)) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (JJ TNFR-associated) (NNS factors)) (PRN (-LRB- -LRB-) (NP (NNS TRAFs)) (-RRB- -RRB-))))))))))) (. .))
(S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (PP (IN in) (NP (JJ EBV-transformed) (NN B) (NNS lymphocytes))) (NP-SBJ-COOD-56 (NP (NP (JJS most)) (PP (IN of) (NP-COOD (NP (NN TRAF1)) (CC or) (NP (NN TRAF3))))) (CC and) (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (NN TRAF2))))) (VP (VBP are) (VP (VBN associated) (NP (-NONE- *-56)) (PP (IN with) (NP (NN LMP1))))))) (CC and) (SBAR (IN that) (S (NP-SBJ-57 (NP (JJS most)) (PP (IN of) (NP (NN LMP1)))) (VP (VBZ is) (VP (VBN associated) (NP (-NONE- *-57)) (PP (IN with) (NP-COOD (NP (NN TRAF1)) (CC or) (NP (NN TRAF3)))))))))) (. .))
(S (NP-SBJ-COOD (NP (NN TRAF1)) (, ,) (NP (NN TRAF2)) (, ,) (CC and) (NP (NN TRAF3))) (VP (VBP bind) (PP (TO to) (NP (NP (DT a) (JJ single) (NN site)) (PP (IN in) (NP (NP (DT the) (NN LMP1) (NN CT)) (VP (VBG corresponding) (PP (TO to) (NP (NP (NP (NN amino) (NNS acids)) (PRN (-LRB- -LRB-) (NP (NNS aa)) (-RRB- -RRB-))) (NP-COOD (NP (CD 199)) (TO to) (NP (CD 214)))))))) (, ,) (PP (IN within) (NP (NP (DT a) (NN domain)) (SBAR (WHNP-58 (WDT which)) (S (NP-SBJ (-NONE- *T*-58)) (VP (VBZ is) (ADJP-PRD (JJ important) (PP (IN for) (NP (NN B-lymphocyte) (NN growth) (NN transformation)))))))) (PRN (-LRB- -LRB-) (NP (NNS aa) (NP-COOD (NP (CD 187)) (TO to) (NP (CD 231)))) (-RRB- -RRB-)))))) (. .))
(S (NP-SBJ-COOD (NP (JJ Further) (UCP (ADJP (JJ deletional)) (CC and) (NP (NN alanine) (NN mutagenesis))) (NNS analyses)) (CC and) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NN TRAF) (NN binding) (NNS sequences)) (PP-COOD (PP (IN in) (NP (NN CD40))) (, ,) (PP (IN in) (NP (NN CD30))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NN LMP1)) (PP (IN of) (NP (JJ other) (NNS lymphycryptoviruses)))))))))) (VP (VBP provide) (NP (DT the) (JJ first) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NN (S PXQXT))) (VP (VBZ is) (NP-PRD (DT a) (NN core) (NN TRAF) (NN binding) (NN motif))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ negative) (NNS effects)) (PP (IN of) (NP (NP (NN point) (NNS mutations)) (PP (IN in) (NP (DT the) (NN LMP1-LRB-1-231-RRB-) (NN core) (NN TRAF) (NN binding) (NN motif))))) (PP (IN on) (NP-COOD (NP (NN TRAF) (NN binding)) (CC and) (NP (NN NF-kappaB) (NN activation))))) (ADVP (RB genetically)) (VP (VBP link) (NP (DT the) (NNS TRAFs)) (PP (TO to) (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation)))) (. .))
(S-COOD (S (NP-SBJ-59 (NP (NN NF-kappaB) (NN activation)) (PP (IN by) (NP (NN LMP1-LRB-1-231-RRB-)))) (VP (VBZ is) (ADJP-PRD (JJ likely) (S (NP-SBJ-60 (-NONE- *-59)) (VP (TO to) (VP (VB be) (VP (VBN mediated) (NP (-NONE- *-60)) (PP (IN by) (NP-LGS (NN (TRAF2 TRAF1)) (NNS heteroaggregates))) (SBAR (IN since) (S (NP-SBJ-108 (NN TRAF1)) (VP (VBZ is) (ADJP-PRD (JJ unique)) (PP (IN among) (NP (DT the) (NNS TRAFs))) (PP (IN in) (S (NP-SBJ (-NONE- *-108)) (VP (VBG coactivating) (NP (NN NF-kappaB)) (PP (IN with) (NP (NN LMP1-LRB-1-231-RRB-)))))))))))))))) (, ,) (S (NP-SBJ (DT a) (NN TRAF2) (JJ dominant-negative) (NN mutant)) (VP (MD can) (VP (VB block) (NP-COOD (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN TRAF1) (NN coactivation)))))) (, ,) (CC and) (S (NP-SBJ-61 (NP (CD 30) (NN %)) (PP (IN of) (NP (NN TRAF2)))) (VP (VBZ is) (VP (VBN associated) (NP (-NONE- *-61)) (PP (IN with) (NP (NN TRAF1))) (PP (IN in) (NP (JJ EBV-transformed) (NN B) (NNS cells)))))) (. .))
(S (NP-SBJ (NN TRAF3)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ negative) (NN modulator)) (PP (IN of) (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation))))) (. .))
(S (ADVP (RB Surprisingly)) (, ,) (NP-SBJ-COOD (NP (NN TRAF1)) (, ,) (NP (NP (-NONE- *?*)) (CD -2)) (, ,) (CC or) (NP (NP (-NONE- *?*)) (CD -3))) (VP (VBZ does) (RB not) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (JJ terminal) (NN LMP1) (NN CT) (NNS aa) (NP-COOD (NP (CD 333)) (TO to) (NP (CD 386)))) (SBAR (WHNP-62 (WDT which)) (S (NP-SBJ (-NONE- *T*-62)) (VP (MD can) (ADVP (RB independently)) (VP (VBP mediate) (NP (NN NF-kappaB) (NN activation)))))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ constitutive) (NN association)) (PP (IN of) (NP (NNS TRAFs))) (PP (IN with) (NP (NN LMP1))) (PP (IN through) (NP (NP (DT the) (NNS aa) (NP-COOD (NP (CD 187)) (TO to) (NP (CD 231))) (NN domain)) (SBAR (WHNP-63 (WDT which)) (S (NP-SBJ (-NONE- *T*-63)) (VP (VBZ is) (ADJP-PRD (JJ important)) (PP (IN in) (NP-COOD (NP (NN NF-kappaB) (NN activation)) (CC and) (NP (JJ primary) (NN B-lymphocyte) (NN growth) (NN transformation)))))))))) (VP (VBZ implicates) (NP (NP (NN TRAF) (NN aggregation)) (PP (IN in) (NP (NN LMP1) (NN signaling))))) (. .))
